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1   Introduction  
 
The flavin-containing monoamine oxidases (MAO, E.C. 1.4.3.4) are redox enzymes found on the 
mitochondrial outer membrane in every animal cell. Their pharmaceutical importance is due to the fact 
that MAOs oxidize neurotransmitters such as serotonin and dopamine, changed levels of which are 
associated with behavioral changes, depression, addiction, aggression and neurodegeneration. High or 
low MAO activity is associated with pathology. For example, elevated MAO B is observed in 
neurodegenerative diseases such as Alzheimer’s disease. Above average activity of MAO A has been 
associated with major depression whereas low MAO A is associated with aggression. 
MAO inhibitors (MAOI) are widely used as antidepressants, mood stabilizers, and to offset the 
effects of brain degenerative diseases such as Parkinson’s disease. The social and economic impact of 
neurodegenerative diseases in society remains a good reason for exploring new inhibitors of MAO to 
elevate remaining neurotransmitters, particularly in multi-target drugs for these complex pathologies.  
MAO catalysis was first characterized in 1928, but it was the observation of the antidepressant effect 
of MAOI that triggered the rise of interest in the enzymes in the 1950s (reviewed in (Tipton, 2018). 
Figure 1 illustrates the scientific interest in monoamine oxidases expanding during the 
pharmacological exploration of MAO inhibitors (MAOI) as drugs, mainly used as antidepressants, 
then beginning to decline in the late 1980s as pharmaceutical interest waned. The publication of the 
crystal structure of MAO B in 2002 and MAO A in 2005 renewed interest and enabled the modern era 
of drug design, engaging chemists in particular in discovery of new compounds using computational 
and high throughput methods (23% of publications from 2005). 
 
 
 
Figure 1. Publications with monoamine oxidase in the title. Note the use of mono-amine oxidase in 1978-79 
(compiled from Web of Science, May 2018).  
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The two monoamine oxidase isoenzymes, MAO A and MAO B, are encoded by genes on the X-
chromosome (MAOA and MAOB) and are expressed in all tissues. In addition to their well-known role 
in the brain, peripheral MAOs especially in gut (MAO A), liver (both), platelet (MAO B) and placenta 
(MAO A) play significant roles in protection against biogenic amines and contribute to Phase 1 drug 
metabolism. In heart, hydrogen peroxide and aldehydes produced by MAO oxidation of amines may 
contribute to heart failure. These flavoprotein oxidases (E.C. 1.4.3.4) are located on the mitochondrial 
outer membrane, and therefore metabolise intra-cellular amines. In contrast, the copper-dependent 
primary amine oxidases (the soluble semicarbazide-sensitive amine oxidase (SSAO) and its membrane 
form, Vascular Adhesion Protein-1, E.C. 1.4.3.21) act on extra-cellular amines and function in 
inflammation (Becchi et al. , 2017). SSAO, lysyl oxidase (1.4.3.13) and diamine oxidase (E.C. 
1.4.3.22 which metabolises histamine) contain 2,4,5-trihydroxyphenylalaninequinone as cofactor 
(www.brenda-enzymes.org). These non-FAD enzymes will not be considered in this article. Other 
FAD–containing oxidases include the related amino acid oxidases, L-amino acid oxidase (LAAO, 
E.C. 1.4.3.2) and D-amino acid oxidase (DAAO, E.C. 1.4.3.3), and spermine metabolising enzyme, 
polyamine oxidase (E.C. 1.5.3.13), all of which have covalently bound FAD. A possible evolutionary 
precursor of MAO is found in the peroxisomes of Aspergillus niger and has a non-covalently bound 
FAD co-factor (Sablin et al. , 1998) making it interesting for chemical applications (Bailey et al. , 
2007). 
 The reaction catalysed by MAO moves two hydrogen atoms to the FAD from the amine forming  
an imine. The reduced FAD is then reoxidized by oxygen to form hydrogen peroxide. The imine 
product is then hydrolysed by water giving the corresponding aldehyde and ammonia (Fig. 2). This 
chapter will consider the structure of the enzyme and the redox reaction with the cofactor and before 
turning to the substrate specificity, kinetics and mechanism that are important for drug design. MAO 
A and MAO B show broad specificity for both substrates and inhibitors, yet can display exquisite 
selectivity as will be discussed in the last section on inhibitors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 The redox reaction catalysed by MAO is followed by spontaneous hydrolysis of the imine product to 
give the aldehyde and ammonia. The FADH2 is reoxidized by oxygen to give the second product, hydrogen 
peroxide. 
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2 FAD: the catalytic cofactor 
 
2.1  FAD  is  covalently  attached  to  MAO    
FAD, a redox cofactor important for catalysis in many enzymes, is derived from the vitamin 
riboflavin. As in most many FAD-containing enzymes, the adenine part of the molecule binds to a 
Rossman fold in the protein. The isoalloxazine ring part of FAD is held in position by a covalently 
bond to a cysteine residue in MAO (Fig. 3). In all crystal structures of MAO B, the isoalloxazine ring 
is bent by about 30° (Binda et al. , 2003) with about 0.3° difference between the oxidized and reduced 
forms. However, molecular dynamics has now enabled a more realistic picture of the shape of the 
flavin in the flexible protein active site. Two different studies have shown that it is almost planar in the 
oxidised form (FAD) (Vianello et al. , 2012, Zapata-Torres et al. , 2015), but when it is reduced either 
by a hydride ion from the substrate transferred to N5 in the first step of the catalytic mechanism or 
after the propargylamine adduct has formed at N5, the FADH2 is bent by almost 30 degrees (Borstnar 
et al. , 2011) in agreement with the crystal structure.  
Covalent attachment (at the C8 position of FAD in MAO), bending, and the surrounding protein 
groups alter the redox potential in flavoproteins. The two-electron redox potential for FAD in solution 
is -0.23 V and is the similar for the cysteinyl-FAD in MAO (about -0.2 V). The redox potential for 
amine oxidation is greater than +1 V, so for amine to reduce MAO requires a large adjustment from 
binding to the protein.  FADH2 readily reacts with oxygen producing hydrogen peroxide (H2O2) (+0.3 
V). In amine oxidases, the reoxidation is thought to proceed via a C4a hydroperoxy intermediate 
(Mattevi, 2006). Although the catalytic reaction is a two-electron reduction, with hydride transfer the 
most likely mechanism, FAD is a versatile one or two electron acceptor. When MAO is reduced by 
dithionite in the presence of mediator dyes, inhibitors stabilize the anionic semiquinone form (Hynson 
et al. , 2004).  
  
  
  
  
 
 
 
 
 
 
 
Figure 3 The 8-a-S-cysteinyl-isoalloxazine ring of FAD in the active site of MAO. The yellow circle at N10 
indicates the rest of the FAD molecule. In MAO B (pdb: 1GOS), the flavin is bonded to Cys397 and the two 
N5 
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tyrosines that are key to the aromatic cage for the substrate are Tyr398 and Tyr 435. The N5 (labelled) is 
involved in catalysis of the redox reaction. 
  
2.2  FAD  is  modified  by  irreversible  inhibitors  
The major pharmaceutical drugs used to inhibit MAO modify the FAD irreversibly. Phenelzine 
(Nardil), tranylcypromine, and deprenyl (Selegiline) represent three classes of MAO inactivators, all 
of which form a covalent bond to the N5 of FAD as shown in Fig 4. Phenelzine and tranylcypromine 
are successful antidepressants achieving about 50% response rates, slightly better than the tricyclic 
antidepressants (Nutt, 2006). Deprenyl is now used in both oral and patch formulations both to delay 
the need for L-DOPA and as adjunct therapy in Parkinson’s disease. Although the structures of these 
MAO-inhibitor adducts were characterized chemically and by the crystal structures, the mechanisms 
of adduct formation remain incompletely understood. Inhibition of MAO will be discussed in more 
detail below. 
 
 
 
 
 
 
 
 
 
 
Figure 4 Irreversible MAO inhibitor drugs all form the N5 adduct with the flavin. The figure was prepared in 
MAcPyMol with the protein main chains aligned. The adducts shown are MAO B with phenelzine (grey, 
2VRM), and deprenyl (1GOS) bonded to N5, and tranylcypromine (cyan, 2XFU) bonded at C4a of the FAD. 
 
3. MAO proteins 
 
3.1 MAO protein expression and activity 
Abnormal MAO activity has long been associated with neuropathology and behavioural changes 
(Finberg and Rabey, 2016). Humans with low MAO A activity and MAO A knockout mice display 
aggression (Bortolato and Shih, 2011). Low platelet MAO B is associated with alcoholism and 
behavioural disinhibition (van Amsterdam et al. , 2006, Bortolato and Shih, 2011). Expression of 
MAO A and B differs by cell type and they are regulated differently. The upstream 30 base pair 
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VTNR polymorphism in the MAO A promotor with 3 or 5 repeats results in as much as a 10-fold 
lower expression compared to the normal 4 repeats(Sabol et al. , 1998), and a downsteam VTNR has 
been reported to decrease expression of a novel isoform (Manca et al. , 2018). Both MAO A and B 
have similar GC-rich promoter regions activated via Sp1 sites. Both promotors are down-regulated by 
the transcription factor R1 but MAO A expression is increased via the Glucagon Receptor Element 
and MAO B expression is increased by retinoic acid (Shih et al. , 2011).  
Epigenetic regulation also plays a role and may provide the link with environmental influence on 
behaviour. One study demonstrated that MAOA promoter hypermethylation was associated with 
antisocial personality disorder and with high serotonin levels via down-regulation of MAO A gene 
expression (Checknita et al. , 2015). Epigenetic influence was explored using allelic expression 
imbalance (AEI) of two single nucleotide polymorphisms in female human brain tissue. AEI ratios 
varied from 0.3 to 4 in prefrontal cortex samples indicating transcription-level regulation of mRNA 
production. CpG methylation in the MAOA promoter region was high in females and the extent of 
allelic MAOA methylation correlated with AEI ratio, showing that CpG methylation regulates gene 
expression (Pinsonneault et al. , 2006). Using molecular biology combined with Positron Emission 
Tomography (PET) to measure regional MAO activity, a robust association of CpG site-specific 
methylation of the MAOA promoter with regional brain MAO A levels was demonstrated, strongly 
supporting the notion that epigenetic status (which can be influenced by environment, such as 
smoking) contributes to inter-individual differences in behaviour (Shumay et al. , 2012).  
The activity of MAO in human brain studied by PET has confirmed earlier studies that recovery of 
MAO activity after inhibition by irreversible inhibitors such as deprenyl is slow, with a half-life of 40 
days in the human brain, because it depends on the replacement of the inactive adduct enzyme with 
newly synthesized protein. PET has also proved useful for dosing studies, indicating that more than 
75% occupancy of MAO active sites is required for clinical efficacy (reviewed in (Fowler et al. , 
2005)). 
 
3.2 Structures and Active Sites 
The first purified MAO B was extracted from beef liver (Salach, 1979) and MAO A from human 
placenta. The first large scale heterologous expression of MAO A in S. cerevisiae provided pure 
enzyme for kinetic studies (Weyler et al. , 1990), but it was high-level expression in Pichia pastoris 
(Newton-Vinson et al. , 2000, Li et al. , 2002) that enabled crystallization first of human MAO B 
protein, and then of rat and human MAO A (Binda et al. , 2002, Ma et al. , 2004, De Colibus et al. , 
2005, Son et al. , 2008). The terminal hydrophobic helix of each of the two subunits of MAO is 
monotopically inserted in the mitochondrial outer membrane and further residues associate with the 
surface of the membrane, so that high amounts of detergent are required to solubilize the protein.  The 
active site details from the crystal structures opened the way for structure-based drug design. 
 7 
Comparison of the rat and human MAO structures revealed minor differences reflecting the reported 
species differences in substrate and inhibitor specificity (Krueger et al. , 1995, Hubalek et al. , 2005, 
Ramadan et al. , 2007). In all structures, the catalytic FAD is at the end of a tunnel leading from the 
surface of the protein. The tunnel is generally hydrophobic, ending in an aromatic cage near the flavin 
where tyrosines (Tyr398 and Tyr435 in MAO B) align the neutral amine substrate towards the C4-N5 
region of the flavin.  The flavin is bent at about 30° along the N5-N10 axis favoring reduction as 
shown in Fig. 3, , and there is a lysine-water-flavin(N5) motif important for the redox reactions of the 
flavin (Binda et al., 2002). 
The two MAOs share 70% sequence identity but the active sites have subtle differences. In 
particular, MAO B has a constriction in the middle of the cavity due to residues isoleucine 199 and 
tyrosine 326 and MAO B has one cysteine (Cys172) not present in the MAO A active site 
(Edmondson et al. , 2007, Milczek et al. , 2011, Orru et al. , 2013). The differences allow discovery or 
design of compounds for selective inhibition, as will be discussed in the inhibition section.  
 
3.3 MAO chemical mechanism  
Supported by extensive molecular model chemistry and recent thermodynamic calculations, three 
mechanisms have been considered for MAO catalysis: the polar nucleophilic mechanism (Orru et al., 
2013), the radical (Silverman, 1995), and the hydride transfer mechanism (Kay et al. , 2007). The 
hydride transfer mechanism (Fig. 5) is found in other oxidases and is supported by theoretical studies 
based on transition state theory (Vianello et al. , 2016). However, the versatility of flavin catalysis 
could allow alternative mechanisms with specific chemicals, for example with the cyclopropylamines. 
 
 
Figure 5 Hydride transfer is a probable mechanism for amine oxidation by MAO 
 
3.4 Two Substrate Kinetics and Consequences for Amine Turnover 
MAO catalyzes the oxidation of amines by molecular oxygen. Depending on the conditions used, 
this two-substrate enzyme can reveal either ping-pong kinetics or a ternary complex kinetic 
mechanism in which a new amine substrate molecule binds to the reduced MAO before reaction with 
 8 
oxygen (Tan and Ramsay, 1993). Fig. 6 illustrates the three possible re-oxidation pathways.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 The catalytic cycle in MAO showing the alternative pathways for re-oxidation of FAD.  
 
Both steady-state and stopped flow kinetics have been used to establish that ligands (substrate or 
inhibitor) can bind to either the oxidized or reduced forms of the enzyme, albeit with very different 
affinities (Tan and Ramsay, 1993, Ramsay et al. , 2011). The proportion of MAO in the reduced state 
will vary depending on the amine concentration, the rates of reduction and oxidation of the flavin, and 
on the oxygen levels. Thus, the turnover of amines in vivo will be influenced by the local 
concentration of oxygen and by the redox state of the enzyme in the presence of the predominant 
substrate (Ramsay, 1998, Sablin and Ramsay, 2001). For MAO A, the rates of the reductive half 
reaction (kred) are all similar to the steady-state rate (kcat), and the oxidative half reaction in the 
presence of amine is faster (kox). For MAO B, the rate of amine oxidation can be faster than kcat. For 
some substrates, notably phenylethylamine, the oxidative half-reaction determines the rate of turnover 
(Table 1). These rates mean that MAO A oxidizing PEA will be predominantly oxidized but MAO B 
will be fully reduced in the steady state. Another important difference between MAO A and B is the 
KM for oxygen. MAO A continues working at low oxygen concentration (KM = 0.06 mM) whereas 
MAO B has a KM close the concentration of dissolve oxygen (0.28 mM), so that the rate of MAO B 
catalysis will decrease with the oxygen concentration in the cell. 
 
Table 1 Rates for turnover (kcat), reductive half-reaction (kred), and the oxidative half reaction in the 
presence of amine (kox) in purified MAO A and MAO B. The data are taken from (Tan and Ramsay, 
1993). 
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4.  Substrate Specificity of these Promiscuous Enzymes 
 
4.1 Neurotransmitter metabolism 
Substrate specificity depends not only on the kcat discussed above but also on the recognition of the 
substrate by the enzyme, measured in kinetic terms by KM. For example, the KM for serotonin in rat 
brain homogenates is 0.18 mM with MAO A but is 1.2 mM with MAO B so clearly serotonin 
concentrations would have to be very high before MAO B contributed much to its metabolism. 
Comparison of specificity is best informed by kcat/KM alongside the expected or measured 
concentrations in the cell. Some values for kcat/KM in rat brain are given in Table 2. Note that the 
location of MAO on the mitochondrial surface means that it is the intracellular concentration of amine 
that is important rather than the synaptic concentration. Reuptake systems bring the extracellular 
amine into the presynaptic nerve terminal where mitochondria are clustered and the storage vesicles 
are also located. The vesicular reuptake system (VMAT2) with affinity for the monoamine 
neurotransmitters of 1.4 µM for dopamine and 0.9 µM for serotonin (Erickson et al. , 1996) efficiently 
clears dopamine to leave cytosolic levels below 50 nM (Mosharov et al. , 2006, Mosharov et al. , 
2009). The MAO that predominates in dopaminergic neurons is MAO A with a KM for dopamine of 
212 µM. In serotonergic cells, MAO B predominates with a KM for serotonin of 1 mM (Youdim et al. , 
2006). Thus most of the neurotransmitters will be returned to storage vesicles and only a very little 
metabolized.  However, inhibition of MAO B in particular raises the overall content of amines in the 
brain. MAO B is the major form in all the non-neuronal cells and has been reported to increase with 
aging and in Alzheimer’s disease, making it an attractive pharmaceutical target to help maintain global 
levels of amines outside the synapses in deteriorating brain. The importance of MAO for metabolism 
of neurotransmitter is apparent in serotonin toxicity where excessive levels of extracellular serotonin 
accumulate. It occurs only when a serotonin reuptake inhibitor is co-administered with a non-selective 
irreversible MAOI (Gillman, 2011). 
 
Table 2  Relative rates of amine oxidation by rat MAO A and MAO B   
Calculated from  (Fowler and Tipton, 1984) .  
Amine MAO A rates (min-1) MAO B rates (min-1) 
 kcat kred kox kcat kred kox 
5HT 2.8 2.1 6 0.08 0.1 2 
PEA 0.75 1.10 12 3.6 572 2 
MPTP 0.20 0.20 40 0.16 0.12 6 
No amine   1   1 
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Substrate Catalytic constant  (V/ KM ) 
µmol. min-1.mg-1.mM-1 
 MAO A MAO B 
Serotonin 540  7  
Tyramine 309 113 
Phenylethylamine 46 4350 
Dopamine 231 232 
Noradrenaline 232 143 
 
 
4.2 Metabolism of biogenic amines 
MAO enzymes in the periphery are important for metabolism of exogenous amine compounds. 
Ingested amines have variable proportions present as the neutral compound that can diffuse cross 
membranes. Where there is a pH difference, such as between cytosol and the mitochondrial matrix, 
reprotonation results in accumulation of the charged species in the new compartment. The 
mitochondrial transmembrane potential also favors retention of positively charged amines. Biogenic 
amines from the diet, principally tyramine, are extensively metabolized in the intestinal wall by MAO 
A (Anderson et al. , 1993). If tyramine increases in the circulation, complex sympathetic nervous 
system perturbations ensue, with consequent vasoconstriction and bradycardia (reviewed in (Finberg 
and Gillman, 2011)). Tyramine accumulation results in this “cheese effect” when MAO A in the gut 
and MAO A and MAO B in the liver are inhibited by non-selective drugs such as tranylcypromine or 
phenelzine. The tyramine-induced cheese effect is avoided by using selective MAO B inhibitors such 
as selegiline in adjunct therapy of Parkinson’s disease or reversible inhibitors of MAO A in depression 
(Lum and Stahl, 2012).  
A wide variety of amine-containing drugs are also metabolized by MAO, contributing 1% of the 
enzymatic metabolism of marketed drugs (compared to 95% by the P450 family) (Rendic and 
Guengerich, 2015). The biotransformation of drugs and other xenobiotics by the amine oxidases in 
contrast to the P450 family has been reviewed (Benedetti et al. , 2001). Metabolism by MAO can also 
transform a compound into a toxic product. A well-known example is the four electron oxidation of l-
methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) by MAO to 1-methyl-4-phenylpyridinium (MPP+). 
The toxic MPP+ is taken up into dopaminergic cells in the substantia nigra and is accumulated into 
mitochondria where it inhibits NADH oxidation by the respiratory chain, hence preventing ATP 
production and consequent dopaminergic cell death leading to Parkinson’s disease (Singer and 
Ramsay, 1990). To avoid such adverse side effects in development of new compounds, computational 
methods for the prediction of probable metabolic products has been developed based on databases of 
approved drugs with well-characterized metabolic profiles (Kar and Leszczynski, 2017).  
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4.3 Products from MAO catalysis 
All amine substrates are oxidized by MAO to the imine which is hydrolysed non-enzymically to 
the corresponding aldehyde (Fig. 1). Aldehydes are somewhat reactive molecules that can damage 
biological molecules by nucleophilic addition. In the cell, aldehyde dehydrogenase metabolizes the 
aldehyde to the carboxylic acid. The second product of MAO catalysis is hydrogen peroxide (H2O2). 
The toxic effect of MAO-generated H2O2 was clearly demonstrate for serotonin metabolism in heart 
(Pena-Silva et al. , 2009). Decreased generation of H2O2 in the brain may contribute to the beneficial 
effects of selegiline. 
 
 
5. Inhibition of MAO 
 
The pharmacological exploitation of MAO inhibitors as drugs began with the serendipitous 
discovery that the tubercular drug iproniazid had antidepressant effects (reviewed in (Tipton, 2018)). 
Despite the cheese effect of the non-selective irreversible inhibitors, the most effect MAO inhibition is 
still achieved by irreversible inhibition. Drugs such as pargyline and tranylcypromine are underused in 
psychiatry, yet the reversible MAO A-selective antidepressant drug, moclobemide, works only in 
some cases of depression. MAO B-selective reversible inhibitors have been slow to appear but 
safinamide (Ki for MAO B 450 nM) has now been approved by the FDA for use as adjunct therapy in 
Parkinson’s disease. The therapeutic potential of MAOI is clearly recognized (Youdim et al., 2006), 
with more recent efforts yielding patents for new reversible inhibitors or for inhibitors that also target 
other features of degenerative disease (multi-target compounds) as will be discussed below. 
 
 
The definitions used for assessment of reversible and irreversible inhibitors discussed here are 
given in Table 3. The best pharmacological approach for MAO inhibition is not clear. Proven history 
of over 50 years has established the effectiveness of irreversible drugs such as selegiline. Extensive 
Table 3. Reversible and irreversible inhibition of MAO 𝐓𝐲𝐩𝐞	   𝐑𝐞𝐚𝐜𝐭𝐢𝐨𝐧	   Measure Comment 
Reversible E	   + 	  I	  	  	  	  	  k12	  	  	  	  	  	  ⇄	  	  	  	  	  k42	  	  	  	  	  E. I 
 
Ki = k-1/k+1 
Reversible binding can be at 
equilibrium, or slow, or tight, 
depending on rates 
Irreversible 
(mechanism-based)  
E	   + 	  I	  	  	  k12⇄k42	  	  E. I	   6789: 	  	  E-I KI and kinact 
Depends on binding, catalytic 
conversion of I, and then 
chemical reaction 
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human studies in vivo over the last 20 years using PET have established that 75-80% inhibition of 
MAO is required before beneficial effects are seen, emphasizing the spare capacity in this enzyme 
(Fowler et al. , 2015a). With irreversible inhibition the effective inhibition is long lasting, with slow 
resynthesis of MAO to replace the inactivated enzyme. Selective irreversible inhibitors of MAO B (for 
example, selegiline) now have a proven safety record, improved by delivery in transdermal patches to 
avoid major inhibition of MAO B in the liver. Reversible inhibitors require constant dosing, and even 
they are not completely free of the cheese effect (Lum and Stahl, 2012). The inhibition of MAO 
increases brain neuroamines, but the subsequent downstream changes in receptors and heterologous 
effects on other neurotransmitter systems are slow. Thus, the prolonged effect of irreversible inhibition 
may be more suited to this set of events. The sections below consider key reversible inhibitors, 
effective tight-binding inhibitors and irreversible inhibitors in turn before looking briefly at new 
computational approaches to drug discovery. 
 
5.1 Reversible inhibitors of MAO 
The reluctance to prescribe irreversible inhibitors for neuoropathology because of the cheese effect 
has supported extensive exploration of new scaffolds by medicinal chemists. Aspects of the reversible 
inhibition from structure-activity studies were reviewed before the publication of the crystal structure 
of the enzymes (Wouters, 1998). More recently, many compounds, mostly with common features of at 
least one aromatic ring and a nitrogen atom, and having a relatively linear structure, have been 
discovered through data mining or by structure-based design. A recent review pulls together the many 
chemical entities that can inhibit reversibly and selectively MAO A or MAO B (Tripathi et al. , 2018). 
Of particular interest are the various derivatives based on the coumarin scaffold, for use as multi-target 
compounds against neurodegeneration (reviewed in (Stefanachi et al. , 2018)). Many medicinal 
chemistry groups are aiming to develop other MAO-A and MAO-B reversible inhibitors, only some of 
which reach the stage of pharmacology (Finberg and Rabey, 2016). In light of the growing scale of 
neurodegenerative disease, promising compounds are promptly patented, and patent updates appear 
regularly, such as one surveying patents of clinical interest filed in 2015-2017 (Carradori et al. , 2018). 
These patents include 108 compounds, both synthetic and from natural sources, including coumarins, 
pyrazoles, and arylamides.  
The initial experimental assessment of novel reversible inhibitors is usually done by determining 
the IC50 values of a series of chemicals. The two-substrate, alternative pathway kinetics described 
above means that great care is required to set conditions that allow measurement of competition with 
the amine substrate: ie, that the amine substrate is rate limiting. For comparison of inhibition of MAO 
A and MAO B, the fractional saturation with amine substrate should be the same (usually 2 or 3 times 
KM). Further details can be found elsewhere (Ramsay et al., 2011, Ramsay and Tipton, 2017). 
Compounds of interest are then characterized to confirm reversibility and identify mode of inhibition. 
 13 
Most inhibitors are competitive with the amine substrate, as can be understood by inspection of the 
active site: both substrate and inhibitor bind in the same place. However, apparent deviation from 
competitive inhibition is sometimes found for MAO B. The MAO B KM for oxygen of 0.23 mM is 
close to the concentration of oxygen in air-saturated buffer at 37°C. The deviations can arise when the 
conditions chosen result in both oxidized and reduced MAO B being present in the steady state, so that 
the affinity of the compound for both forms influences the shape and concentration-dependence of the 
dose-response curve (Ramsay et al., 2011).  
The one clear example of mixed inhibition that has been fully established is for the imidazoline 
compound 2-(2-benzofuranyl)-2-imidazoline (2-BFI). The 2-BFI binds in the entrance cavity of MAO 
B when the cavity is in a particular conformation that can be stabilized by tranylcypromine bound in 
the catalytic site (Bonivento et al. , 2010, McDonald et al. , 2010). The I2-type imidazoline compounds 
bind to a subset of MAO molecules with nanmolar affinity but inhibition of the bulk population of 
MAO requires micromolar concentrations (Jones et al. , 2007, McDonald et al., 2010). The 
significance of imidazoline binding to MAO in the cell is not clear. 
 
 
5.2 Examples of tight binding reversible inhibitors of MAO 
The rate of binding of harmine to MAO measured by rapid scan stopped-flow spectrometry was 
2x108 M-1 s-1, close to diffusion-limited rate. Yet the onset of inhibition in a steady-state assay 
required almost 2 minutes. Many inhibition studies preincubate the ligand and enzyme for 5 -30 min 
before adding substrate to start the reaction. This allows equilibrium of the inhibitor in the absence of 
substrate (binding affinity) but if the off-rate is slow, curvature of the time course in the presence of 
substrate will be observed. Thus, continuous assays with or without preincubation can give additional 
information. The harmine on-rate is fast, so its off-rate must be slower giving the tight-binding Ki of 5 
nM (Kim et al. , 1997).  
The thionine dye, Methylene Blue also binds tightly to MAO A. Clinical uses (surgical, 
antimalarial) and preclinical information on the dye, methylene Blue (MB) have recently been 
reviewed (Delport et al. , 2017). MB inhibits nitric oxide synthase, guanyl cyclase and MAO A, the 
latter with a Ki of 28 nM (Table 4). Its potency as an MAO inhibitor in vivo became evident as a result 
of serotonin syndrome, sometime fatal when it was administered during surgery to patients taking 
serotonin reuptake inhibitor antidepressants (Gillman, 2006).  MB also acted as an electron donor and 
acceptor with MAO A (Ramsay et al. , 2007) as it does in mitochondria (Delport et al., 2017). 
Safinamide binds tightly to MAO B but also blocks voltage-gated sodium and calcium channels, 
and inhibits glutamate release in rat hippocampal synaptosomes (Caccia et al. , 2006, Stocchi et al. , 
2006). Safinamide, a selective reversible inhibitor of MAO B (Table 4, (Binda et al., 2007), was used 
to explore the structural effect of the two residues specific to the active site of MAO B. Isoleucine 119 
 14 
and tyrosine 326 constrict the cavity of MAO B into entrance and catalytic parts whereas MAO A 
does not have this “gate”. Long ligands such as safinamide span this gate, pushing it “open” and 
flexing around the constriction. MAO A has a wider active site without this constriction so that 
safinamide binds poorly (Ki = 365 uM, Table 4). The strong inhibition of MAO B by safinamide was 
increased from 450 nM to 21 nM after the mutation to alanine of Ile199, one of the gating residues 
between the entrance and catalytic cavities of MAO B. However, in the double mutant, Ile199Ala-
Tyr326Ala, affinity was much less (Ki = 4 µM (Milczek et al., 2011)).  
 
 
 
Table 4 Examples of drugs that inhibit human MAO A and MAO B   
Drug Indication MAO A MAO B Reference 
  Ki (µM) Ki (µM)  
Reversible     
D-Amphetamine Controlled  18  250  (Ramsay and Hunter, 2002) 
Harmine Endogenous 0.005  121a (Kim et al., 1997, Reniers et 
al. , 2011)  
Methylene Blue Trial AD 0.028  5.5  (Ramsay et al., 2007) 
Moclobemide Depression  11.5 >100 (Da Prada et al. , 1989, Curet 
et al. , 1996) 
Pirlindole Depression 0.045 >100 (Medvedev et al. , 1999) 
Safinamide PD adjunct 365 0.45  (Binda et al. , 2007)  
     
Irreversible  IC50b (µM) IC50b (µM)  
 
Clorgyline 
 
Imaging 
 
0.0004 
 
3.57 
 
(Malcomson et al. , 2015) 
Deprenyl (Selegiline) PD adjunct 16.9 0.004 Unpublishedc 
Pargyline Depression 2.47 0.0077 Unpublishedc 
Tranylcypromine Depression 0.237 0.074 (Malcomson et al., 2015) 
Phenelzine Depression 4.50 9 (Binda et al. , 2008)  
Isocarboxidd Depression 0.3 0.18 (Da Prada et al., 1989)  
     a Estimate from invalid use of Cheng-Prusoff equation.  bIC50 values from different labs show considerable 
variation. cIn the unpublished data, activity was measured, using 1 mM tyramine as substrate, after 30 minutes 
pre-incubation of MAO with the inhibitor. (P.L. Joffrin (2016) Honours Thesis, University of St Andrews). dRat 
brain – the reference also includes values for some of the other irreversible inhibitors in rat brain homogenates. 
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5.3 Examples of irreversible inhibitors of MAO 
Table 4 lists the irreversible inhibitors of MAO in clinical use. The three major classes of drugs 
that form covalent adducts with MAO are the older hydrazines (phenelzine, isocarboxazid), a 
cyclopropylamine (tranylcypromine), and the propargylamines (pargyline, clorgyline, deprenyl). 
The general scheme in Fig. 7 shows initial enzyme-catalyzed oxidation of the inhibitor to an 
activated product that either decays to product or reacts with the enzyme (N5 of the FAD for 
theses compounds) to form a covalent adduct. This section will discuss the molecular interactions 
of the three classes of compounds rather than the extensive pharmacological data from rat studies or 
from the clinic.  
 
 
Figure 7 Mechanism-based inhibition of MAO: the reactive product can either dissociate or react to form a 
covalent adduct. 
 
The original discovery of the antidepressant effect of hydrazines came from the observation of 
mood elevation in tuberculosis patients treated with isoniazid.  Hydrazines were then characterized as 
effective MAO inhibitors (Zeller et al. , 1955). Both phenelzine and isocarboxazid carry the risk of 
liver toxicity but remain useful for treatment-resistant depression. The reversible inhibition of MAO 
by phenelzine is poor (Ki is 47 µM for MAO A, 15 µM for MAO B (Binda et al., 2008)), as it is in rat 
and pig brain (Tipton and Spires, 1971). Inactivation requires that the hydrazine acts first as a 
substrate. The product from the oxidation of the hydrazine could be either an imine that is hydrolysed 
to the aldehyde and released as usual with concomitant H2O2 production, or the product could be a 
diazene that reacts with oxygen giving a radical that could alkylate the flavin. Inactivation of MAO A 
and of MAO B follow the same O2 dependent mechanism with some turnover for each inactivation 
event (the partition ratio). The kinetics of inactivation give kinact/Kinact equal to 18 min-1M-1 for MAO A 
and 3 min-1M-1 for MAO, B both with a partition ratio of turnover to inactivation of about 40 (Binda et 
al., 2008). The crystal structure shows that the adduct formed is at N5 of the FAD (Fig. 4).  
Tranylcypromine (TCP) inactivation of MAO has been studied in depth using a variety of 
cyclopropylamine derivatives. TCP itself modifies the flavin at the C4a position (Fig. 4) but N-cyclo-
α-methylbenzylamine modifies a cysteine. Chemical and mechanistic studies of the inactivation 
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support a radical mechanism in which one electron passes from the substrate amino group to the 
oxidized flavin to give the amine radical cation and the flavosemiquinone, followed by opening of the 
cyclopropyl ring and adduct formation (Silverman, 1995). Where adduct formation does not occur, 
further oxidation gives the iminium ion which can either leave the active site or react with nearby 
cysteines. Reversible inhibition by TCP is weak at around 100 µM for both MAO A and B (Table 5) 
(Bonivento et al., 2010, Malcomson et al., 2015). Inactivation with low partition ratios in both forms, 
is marginally better in MAO B (kinact/Kinact  is 0.2 compared to 0.1 min-1. µM-1 in MAO A). 
Interestingly, in MAO B the covalently bound TCP stabilizes the entrance cavity residues to favour 
binding of 2-BFI, an imidazoline site ligand (Bonivento et al., 2010, McDonald et al., 2010). The 
clinical pharmacology for tranylcypromine use in depression has recently been reviewed in a meta-
analysis which found that, when administered with dietary restriction of tyramine, it is a safe and 
effective antidepressant (Ricken et al. , 2017). 
 
 
The propargylamine class of inactivators provides clear examples of the importance of initial 
ligand binding in selectivity, as seen in the 100-fold better Ki for deprenyl on MAO B than for MAO A 
(Table 5). As with both the hydrazines and cyclopropylamines, the first step in inactivation by 
propargylamines is the mechanism-based oxidation to the propargylimine.  With the product retained 
in the active site by the positive charge, the allenyl resonance form undergoes nucleophilic attack by 
the FADH−  forming a substituted 1,3-diaminoallene which, mediated by a water molecule, rearranges 
to the final delocalized product. The stable adduct to N5 (Fig. 4) is the same for all propargylamines 
studied (Binda et al. , 2005, Albreht et al. , 2018). The rate constants for inactivation (kinact) are similar 
in MAO A and MAO B (Table 5) but the Kinact values reflect the selectivity of pargyline and deprenyl 
for MAO B inactivation. An even bigger selectivity difference is seen in the partition ratios for 
Table 5 Kinetic parameters for initial binding and for inactivation of MAO by 
irreversible inhibitors. 
 
 MAO A MAO B 
Compound Ki  
(µM) 
Kinact  
(µM) 
kinact  
(min-1) 
Ki  
(µM) 
Kinact  
(µM) 
kinact  
(min-1) 
Phenelzine 47 3.1 0.12 15 0.9  0.9 
Tranylcypromine 91 7.7 0.77 105 0.16 0.16 
Pargyline 15 22 0.65 1.8 0.35 0.35 
Deprenyl 75 193 0.25 0.97 103 0.53 
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deprenyl: 482 in MAO A but only 1 for MAO B, indicating that every oxidation results in adduct 
formation in MAO B but that 482 product molecules are released from MAO A for each inactivation 
event. Thus, design of the optimum propargylamine inactivator must consider initial binding, 
oxidation rate and product retention and reactivity with the reduced flavin. 
In the propargylamine class, pargylamine has been in clinical use longest but deprenyl now leads 
the market as adjunct therapy for Parkinson’s disease. The highly MAO A selective clorgyline and 
MAO B selective deprenyl are used in PET scans (Fowler et al., 2015a). It must be noted that, under 
chronic administration of higher doses, each of these selective inactivators will inactive the other form 
of the enzyme (Fowler et al. , 2015b). 
 
6. Computational innovation 
The irreversible inhibitors are clinically important and the propargylamine moiety is of particular 
interest for combination into multi-target drugs (see below). Advance drug design is facilitated by 
good crystal structures, by mechanistic understanding and by large datasets of tested compounds as 
well as libraries of fragments to allow discovery of novel compounds to inhibit the enzyme. The rapid 
expansion of computational power to analyze large data and development of algorithms and programs 
techniques to explore the information has provided major advances in the last 10 years. 
 
6.1 Theoretical elucidation of mechanism 
Insight into the mechanism has come from transition state theory using multiscale simulations to 
calculate the free energy barriers for the catalytic step in the oxidation of amines by MAO (reviewed 
in (Vianello et al., 2016). The lower the free energy barriers between substrate, transition state 
internediate, and product, the faster the reaction. The highest resolution structure of MAO was 
optimized, fitted to the electrostatic potential, and the solvent reaction field included, then EVB 
calculations applied to the oxidation of a substrate such as dopamine by lumiflavin in the gas phase 
compared to the reaction in the enzyme. The work revealed that dopamine is stripped of its proton 
(pKa 8.3) for the catalytic reaction that requires the neutral amine before oxidation via a two-step 
hydride transfer in which H- (one proton and two electrons) is transferred to the N5 of the flavin and 
the other H+ is removed from the substrate nitrogen and transferred via a water relay to N1 of the 
flavin to yield the neutral product required for dissociation. The calculated energy for the reaction was 
16.1 kcal/mol in good agreement with the experimentally determined 16.5 kcal/mol. The method not 
only provides insight into the mechanism but also provides information relevant to design of the 
propargylamine inactivators of MAO. As described above, these mechanism-based inhibitors are first 
oxidized as substrates generating a positively charged product that could be retained close to the 
reduced flavin by electrostatic attraction and by favorable cation-π interactions in the active site 
“aromatic cage”, where it can react with the reduced flavin to form a covalent adduct (Albreht et al., 
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2018).  
 
6.2 Data-mining and tools for drug discovery 
By far the most important computational advance for drug discovery has been the ability to search 
databases of millions of compounds for “hits” – compounds with a pharmacophore that will have good 
affinity for a target binding site. With a clinically and biologically validated target identified,  
crystallized proteins and proven ligands enable the development of the descriptors for key interactions 
with the target binding site. The phamacophore derived from effective, selective molecules allows 
chemi-informatics to identify similarity-based compounds and, with advanced data-mining, to exclude 
binding to undesirable off-targets (Nikolic et al. , 2015). The dual resource of ligand and target 
information provides the basis for virtual screening that is now routine in drug discovery. Objective 
ranking of the hits can then be achieved by docking and model refinement. Molecular dynamics to 
check the ligand to protein fit is also important, allowing for the target flexibility, and subsequent 
optimization of the ligand structure. A much shorter list must then be synthesized and experimentally 
verified. The process has recently been summarized with examples across target fields (Ramsay et al. , 
2018). 
To address the failure rate between ligand and drug, many computation approaches have been 
developed for the optimization of druggability, blood-brain barrier penetration, lipophilicity, and 
metabolism. All the computational approaches contribute to more cost-effective discovery and 
optimization of compounds, accelerating progress toward the clinic. Such high-throughput methods 
with the power to consider multiple targets at the same time are particularly effective and useful for 
designing multi-target drugs as will be considered in the next section. 
 
7 Conclusion: the future for MAO inhibition in multi-target drugs 
 
The concept of multi-target drugs (MTD) to treat complex, multifactorial diseases such as 
neurodegeneration and cancer emerging at the beginning of this century. By 2017, 21% of the new 
compounds approved by the US Food and Drug Administration (FDA) for clinical use were aimed at 
more than one target, a testament to the rapid progress facilitated by computational approaches and 
high through-put technology as well as the progress in target identification and assay development at 
the experimental level, drugs against cancer and neuropathologies were the largest classes of these 
MTD (Ramsay et al., 2018). MAOI with their proven effects of slowing the breakdown of 
neurotransmitters are a key part of the anti-neurodegenerative MTD. 
Examples of MTD already on the market include inhibitors of neurotransmitter reuptake systems 
(SNRIs) and antagonists for combinations of receptors such the dopamine D2, serotonin 5-HT2A  and 
α1-adrenergic receptors that can treat schizophrenia.  For the brain, the main enzyme targets for recent 
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compound discovery have been the cholinesterases (ChE) that modulate release of other 
neurotransmitters, the monoamine oxidases (MAO) to elevate levels of monoamines, and beta-
secretase 1 (BACE1) to decrease the generation of the toxic amyloid beta (Aβ) peptide. One 
compound that has been studied in phase 2 clinical trials for cognitive impairment is ladostigil which 
combines two pharmacophores taken from rivastigmine (a ChE inhibitor) and rasagiline (a 
propargylamine inactivator of MAO). Ladostigil inhibits acetylcholinesterase, butyrylcholinesterase, 
and monoamine oxidases A and B, and has neuroprotective effects (reviewed in (Finberg and Rabey, 
2016)). The main dilemma in the design of multi-target drugs is choosing the correct targets, and 
finding the correct balance of potency for all targets in one compound in order to have the desired 
effect in vivo. 
Although inhibition of the enzyme catalysts decreases turnover, inhibition of receptors stops 
cascading of signals. This led to the design of a tripotent compound to inhibit known enzyme targets 
(ChE and MAO) that also blocks the histamine receptor H3, inhibition of which is known to elevate 
acetylcholine, serotonin, dopamine and norepinephrine in the central nervous system. The resulting 
tripotent compound, contilisant, may be a useful MTD in neurodegenerative diseases (Bautista-
Aguilera et al. , 2017).    
Medicinal chemical approaches, facilitated by computation, will provide many more similar 
candidates in the future. However, pharmacology to identify and validate the correct targets remains 
the key step in getting the correct compounds into clinical trials and on towards the market. 
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